HCT116 CDK2-/-, HCT116 CDK2-/- p53-/- cells

Case ID:
C10680

C10680: HCT116 CDK2-/-, HCT116 CDK2-/- p53-/- cells

Value Proposition:

ADVANTAGES

• Somatic cell knockout
• Cell line for validation of CDK2 inhibitors
• Cell line for discovery of new anticancer therapeutics

Technical Details:

Cyclin Dependant Kinase 2 (CDK2) is a member of a large family of protein kinases that initiates the principal transitions of the eukaryotic cell cycle. Mutations in the CDKs and/or their inhibitors are associated with several forms of cancer, making cyclin-dependent kinases important drug targets for cancer therapy. Tumor protein 53 (p53), is a transcription factor that regulates the cell cycle and thus functions as a tumor suppressor that is involved in preventing cancer.

JHU scientists have developed two CDK2 based knockout cell lines. HCT116 CDK2-/- is a CDK2 somatic knockout cell line while HCT116 CDK2-/- p53-/- is a cell line with both CDK2 and p53 knocked out.

Looking for Partners:

Commercial applications for these cell lines include use for validation studies of CDK2 inhibitors and the discovery of new anticancer therapeutics.



Patent Information:
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Sahil Aggarwal
sahil.aggarwal@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum